Leveron&Nexovas
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 1117  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (1,706 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 » Introduction
 » Patients and Methods
 » Results
 » Discussion
 » Conclusion
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    Viewed4276    
    Printed99    
    Emailed0    
    PDF Downloaded152    
    Comments [Add]    
    Cited by others 3    

Recommend this journal

 


 
Table of Contents    
ORIGINAL ARTICLE
Year : 2016  |  Volume : 64  |  Issue : 3  |  Page : 419-427

Cognitive impairment in idiopathic Parkinson's disease


1 Department of Neurology, R. G. Kar Medical College and Hospital, Kolkata, West Bengal, India
2 Department of Neurology, Bangur Institute of Neurosciences, Kolkata, West Bengal, India
3 Department of Neurology, King's College Hospital, London, UK

Date of Web Publication3-May-2016

Correspondence Address:
Dr. Atanu Biswas
Department of Neurology, Bangur Institute of Neurosciences, 52/1A, S. N. Pandit Street, Kolkata - 700 025, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.181533

Rights and Permissions

 » Abstract 

Background: Cognitive symptoms are common in advanced Parkinson's disease (PD). However, assessment of cognitive impairment is difficult in PD because of accompanying motor symptoms and the coexistence of nonmotor symptoms. Specific subdomains affected in the disease are not reflected in the conventional scales used for assessing cognition.
Objectives: This study was aimed at looking at the spectrum of cognitive impairment in the various phenotypes and stages of PD and the correlation of cognitive impairment with motor and nonmotor symptoms of PD.
Patients and Methods: Fifty PD patients fulfilling the UK PD Society Brain Bank's criteria were selected after obtaining explicit consent. Patients were assessed clinically and by using various scales like Scales for Outcomes in PD-Cognition (SCOPA-COG), mini-mental state examination, and Beck's Depression Inventory and Scoring.
Results: The mean age was 58 years, 82% of the patients were male, and the mean modified Hoehn and Yahr staging was 2. The most commonly affected domains were memory and executive functioning. Cognitive impairment was more in those with late-onset disease, more advanced stage of disease, and in the postural instability and gait disorder (PIGD) subgroup. The cognitive function deteriorated with increasing age and duration of the illness. Significant correlation with cognitive impairment was obtained for the manifestations of increased motor disability, presence of coexistent psychotic symptoms and depression.
Conclusions: Cognitive impairment was common among PD patients, and it was more prevalent with increasing duration of the disease, in older patients, in late-onset disease, and in the PIGD subgroup. Increasing motor disability and associated psychotic symptoms as well as depression significantly increased the cognitive impairment.


Keywords: Cognitive impairment; Parkinson disease; postural instability and gait disorder; scales for outcomes in Parkinson's disease-cognition


How to cite this article:
Das D, Biswas A, Roy A, Sauerbier A, Bhattacharyya KB. Cognitive impairment in idiopathic Parkinson's disease. Neurol India 2016;64:419-27

How to cite this URL:
Das D, Biswas A, Roy A, Sauerbier A, Bhattacharyya KB. Cognitive impairment in idiopathic Parkinson's disease. Neurol India [serial online] 2016 [cited 2022 Aug 16];64:419-27. Available from: https://www.neurologyindia.com/text.asp?2016/64/3/419/181533



 » Introduction Top


Over the past few years there has been an increasing awareness that the clinical spectrum of Parkinson's disease (PD) is much broader. Apart from the known motor features, it also encompasses nonmotor domains, including cognition. The spectrum of cognitive impairment in PD ranges from very subtle impairment to frank dementia. The cognitive impairment has a profound effect on the patient's quality of life and also imposes considerable burden on the caregiver. However, the motor impairment makes it difficult to administer cognitive tests in these patients, which often require good motor skills. Very few studies have attempted to study the cognitive impairment in PD, particularly from India. The lack of proper definition of cognitive impairment in PD and nonuniformity of the scales used to assess it in these studies has led to confusing results. In a recent hospital-based prospective study from India, Sanyal et al., reported that among 250 PD patients, 36.8% had no cognitive impairment (PD-normal), 27.2% had PD with dementia (PDD), and 36% had mild cognitive impairment (PD-MCI) at baseline. After 7 years of evaluation, 32 new patients, 12 patients from the PD-MCI group, and nine patients from the PD-normal group were diagnosed with dementia. The 7-year prevalence rate for dementia was estimated to be 49.28%.[1] Few Indian studies have so far appropriately addressed the issue of cognitive dysfunction in PD in a systematic manner using validated scales.

Aim and objectives

To analyze the spectrum of cognitive impairment in various phenotypes and stages of PD and to assess the correlation of this impairment of cognition with motor and various nonmotor symptoms of PD.


 » Patients and Methods Top


Study design

This was an observational, cross-sectional study carried out in a tertiary neurology referral center in Eastern India. Fifty PD patients fulfilling the United Kingdom PD Society Brain Bank criteria were included after obtaining an explicit consent. One of the inclusion criteria was that the patients were able to read English as well as the local language Bengali. The patients were assessed clinically and scored according to various scales used in this study. Patients with aided visual acuity of ≤6/18 or with a significant hearing difficulty were excluded from the study. An ethical clearance for the above mentioned study was obtained from the Institutional Ethical Committee and written consent from the patients was obtained before the study was undertaken.

Assessments

In this study, sociodemographic and historical data were obtained from each patient. In addition, validated scales devised by the Leiden University Medical Center, Department of Neurology, Leiden, the Netherlands, as a part of the Scales for Outcomes of PD (SCOPA) project, were used. These are specifically suited for assessment of PD patients. We have used three scales: Short Parkinson's evaluation scale (SPES)-SCOPA for motor symptoms (motor evaluation, activities of daily living, and motor complications),[2] SCOPA-cognition (SCOPA-COG)[3] for cognitive domains (memory, attention, executive function, and visuospatial function), and SCOPA-psychiatric complications (SCOPA-PC)[4] for psychotic symptoms and impulse control disorders.

A mean score for tremor was calculated as the mean of the following items from the SPES-SCOPA motor scale: Rest tremor (right and left) and postural tremor (right and left). Similarly, a mean score for postural instability and gait disorder (PIGD) was calculated as the mean of postural instability, freezing during the ''on,'' phenomenon, gait score, and walking score. Patients with a ratio of mean tremor score/mean PIGD score ≥1.5 were classified as tremor dominant, whereas patients with a ratio of <1.5 were classified as PIGD dominant.

In order to assess the stage of motor impairment, the modified Hoehn and Yahr staging was applied. Stage 4 and 5 are referred to as “severe impairment,” Stage 3 as “moderate impairment,” and others were labeled as having “mild impairment.”[5] PD was considered as “Early Onset” when the disease started below 40 years of age and “late-onset” when the disease started above 40 years of age.

Cognitive assessment was done by SCOPA-COG [3] and mini-mental state examination (MMSE).[6] There are various components in SCOPA-COG scale, each having a maximum possible score. The lower the score, more is the impairment. The various components include memory (total score 22), attention (total score 4), executive functions (total score 12) and visuospatial functions (total score 5). The maximum possible total score in SCOPA-COG is 43, whereas the maximum possible total score in MMSE is 30. We used Beck's Depression Inventory (BDI) to assess the severity of the depressive symptoms. Before using BDI in our study population, we had translated and validated it. The original BDI was translated into Bengali by a neurologist, a psychiatrist, and a psychologist independently. These translations were pooled together, and a final version was prepared. The Bengali version was then translated back into English. The translation-retranslation reliability was found to be satisfactory. The Bengali version was then used for the study. Patients with a BDI score ≥17 were classified into the group labeled as “patients with depression.” Others were labeled as belonging to the “no depression” group. SCOPA-PC was applied to record the psychotic and impulse disorders.

Statistical analysis

International Business Machine's Statistical Package for the Social Sciences by V 19 was used to perform the statistical analysis. Frequencies and descriptive statistics were examined for each patient. To analyze the correlation between impairment of cognition with motor and nonmotor symptoms, the Pearson's correlation coefficient was used. To analyze the relative contribution of variables such as age, duration of illness, SPES-SCOPA score, depression score, and psychotic symptoms score in influencing the SCOPA-COG scores, the linear regression model was applied.

The Student's t-test was used to analyze if there was a significant difference between the groups of “early-onset” and “late-onset” patients, between the mean cognitive scores of “mild” and “moderate” patients, as well as between the mean cognitive scores of tremor-predominant and PIGD patients.


 » Results Top


The total study population comprised 41 men and 9 women. The mean age of the male population was 59.61 years (standard deviation [SD] =9.716) and that of women was 50.78 years (SD = 6.534). The mean duration of illness was 5.18 years (SD = 4.231). The majority of the study population had tremor-predominant PD (n = 46) and PIGD patients comprised a minority (n = 4). Seventy-eight percent of the PD patients were in the mild Hoehn and Yahr stage (≤2.5) whereas 22% were in the moderate stage (Stage 3).

The cognitive profile of the study population was best reflected when the patients were assessed by the SCOPA-COG scale in contrast to the MMSE. In the study population, the median scores in the various subdomains were 6, 2, 6.5, and 3 for memory, attention, executive, and visuospatial functions, respectively, and the median total score in the population was 18.5 [Figure 1]. In MMSE, the median scores of the various domains were 10 for orientation, 3 for registration, 6 for attention and recall, and 8 for language, and the median score of MMSE was 26.5 [Figure 2]. Thus, it is appreciable that in most of the study population, the scores in MMSE were almost normal. None of our PD patients were found to be suffering from dementia.
Figure 1: Total scales for outcomes in Parkinson's disease-cognition score and scores of its various subdomains of study population

Click here to view
Figure 2: Total mini-mental state examination score and scores of its various subdomains of study population

Click here to view


The comparison between the groups was done according to the age of onset, disease phenotype, and stage of disease. Student's t-test failed to reveal a statistically reliable difference between the mean cognitive scores of “early-onset” (mean = 18, SD = 5.627) and “late-onset” patients (mean = 17.56, SD = 6.041), t (48) = 0.181, P = 0.857, and α = 0.05 [Figure 3]; similarly, we did not find any difference between the mean cognitive scores of “mild” (mean = 18.21, SD = 5.859) and “moderate” patients (mean = 15.55, SD = 5.959), t (48) =1.324, P = 0.192, and α = 0.05 [Figure 4]; and, between the mean cognitive scores of tremor-predominant (mean = 17.76, SD = 5.801) and PIGD patients (mean = 16, SD = 8.124), t (48) =0.566, P = 0.574, and α = 0.05) [Figure 5].
Figure 3: Comparison of scales for outcomes in Parkinson's disease-cognition scores between early and late-onset Parkinson's disease

Click here to view
Figure 4: Comparison of scales for outcomes in Parkinson's disease-cognition scores between mild and moderately impaired patients

Click here to view
Figure 5: Comparison of scales for outcomes in Parkinson's disease-cognition scores between PIGD and tremor-dominant patients

Click here to view


As seen from the matrix [Figure 6], there is a decreasing trend of cognitive scores with increasing age, duration of illness, increasing motor scores, psychotic symptoms, and depressive scores. Levels of significance have been attained for the SPES-SCOPA, SCOPA-PC, and BDI scores.
Figure 6: Composite scatter diagram showing correlation between various studied parameters

Click here to view


From the study, an attempt was made to see the relative contribution of variables like age, duration of illness, SPES-SCOPA scores, depression scores, and psychotic symptoms scores in influencing the SCOPA-COG scores by the linear regression model. This regression model was statistically significant (P = 0.38) with the standard error of the estimate being 5.50, and the model was able to predict about 14% variance in the dependent variables from the independent variables with the larger contribution being from depression followed by the SPES-SCOPA and SCOPA-PC scores.


 » Discussion Top


In this study, we have found that in the PD patients, cognitive impairment is quite common in the early stages of the disease. The deficits are commonly observed in a few selected domains and the conventional MMSE is not sensitive enough to pick up the deficits. In contrast, the use of scales specifically designed to study the affected domains in PD were best suited to detect the deficits. This may reflect the pathophysiology of the disease itself. The difficulties in assessing cognitive impairment in PD patients are manifold. The motor symptoms limit the ability of the patients in performing various cognitive tasks, which require a certain amount of motor functioning. The presence of other associated nonmotor symptoms like depression and psychoses may contribute to the cognitive impairment. Finally, the effect of antiparkinsonian drugs may interfere with the proper cognitive assessment. The impairment is more in the PIGD phenotype compared to the tremor phenotype, though the difference is not statistically significant. In this study, we have tried to analyze the various factors which might be important to predict the onset of cognitive deficits, such as disease severity, motor symptoms, associated depression, and psychotic symptoms.

The underlying pathology of cognitive deficits and dementia associated with PD has been a matter of controversy, both in terms of the site and the type of pathology. Studies of clinicopathological associations in demented patients with PD can be broadly classified into three groups on the basis of pathological changes such as subcortical pathology, limbic or cortical Lewy-body-type degeneration, and those suggesting coincident Alzheimer's disease-type pathology.[7] In a study by Muslimovic et al.,[8] it was seen that compared to either healthy control subjects or normative data, PD patients exhibited impaired performance on a wide range of standardized neuropsychological tests. However, further analysis of individual test performances revealed that deficits in the domains of memory, attention, and executive function constituted the core impairment.

The relationship between PIGD and dementia has been investigated in only a few studies. These have shown that PIGD is more prevalent in demented than in nondemented patients with PD, and that impairment of speech and balance at baseline predicts the incident dementia in PD patients followed longitudinally.[9],[10] In a study by Alves et al.,[11] it was seen that in patients with persistent tremor dominant  Parkinsonism More Details, the MMSE scores were stable during the entire study period, while in those patients who transformed from the 'tremor dominant' to the 'PIGD motor' subtype, this transition was associated with a more than 3-fold increase in the rate of MMSE decline. These findings may indicate that the PIGD subtype and the cognitive decline in PD are caused by common or parallel neuropathological changes. Similarly, in the CamPaIGN study [12] of incident PD, the severity of nontremor type (like mixed, or PIGD type) motor symptoms was associated with a higher risk for the development of dementia that was independent of age.

Cognitive dysfunction in early PD patients may reflect neuropathological changes that are distinct from those responsible for the motor disorder.[13],[14],[15],[16],[17],[18] Further support for this assumption is deduced by the lack of association between cognitive impairment and dopaminergic medication. Cognitive deficits in PD are traditionally seen as subcortical in nature as several studies have demonstrated that there is a significant impairment in executive functions such as poor planning, sequencing, cognitive flexibility, and problem-solving capacities.[12],[19],[20],[21],[22],[23] Memory impairments including encoding, recall, and procedural memory are also affected. Several risk factors for PDD have been proposed, including certain predominant motor features such as rigidity and gait instability, minimal cognitive impairment, and the presence of visual hallucinations.[24],[25] It has been estimated that bulbar dysfunctions and gastroenterological and urological disorders, suggestive of autonomic dysfunction, are predictors of the risk for development of dementia in PD.[26],[27] Older age is widely accepted as a risk factor for dementia in PD.[28],[29] Some authors have found parameters such as disease duration, age of onset, and severity of motor symptoms to be significant risk factors, but the published data are at times contradictory.[30],[31],[32]

There are only few studies conducted in India to assess the cognitive impairment in patients with PD [Table 1]. The investigators of these studies have worked on the subject looking from different angles using various scales. Ours is the first attempt from India to study the subject in a comprehensive manner with the use of standard scales.
Table 1: Comparison of studies on cognitive function in patients with Parkinson's disease from India

Click here to view


Limitations of the study

A few limitations of our study are worth mentioning. This being a tertiary care-centered clinic-based cross-sectional study, it might not reflect the true picture in the community and the progression of symptoms over time cannot be studied from the present design. The sample size was small with mostly male patients with the majority of patients being in the mild and moderate stages. Hence, the deficits represented in this study are not characteristic of the entire spectrum of the disease. Most of the patients were already on dopaminergic medications by the time they presented to us and that may have played a contributory role in the impaired cognitive performance. We would like to continue this study to include more patients and incorporate patients in the advanced stages and in different age groups. They will be subsequently followed up over time so that we can have a clear picture of the burden of these symptoms in the population and follow the evolution of symptoms over time.


 » Conclusion Top


From our study, we conclude that the commonly affected subdomains in PD are memory and executive functioning. Cognitive impairment was more in the groups labeled as late-onset compared to early onset, moderate disease to mild disease, and PIGD to tremor-dominant subgroups but the levels did not achieve statistical significance. A decreasing performance on the cognitive assessment scales was observed with increasing age and duration of the illness. A significant correlation was obtained with increased motor disability, psychotic symptoms, and depression.

Acknowledgment

We wish to thank Mrs. Trishita Das for her kind support in finalizing the document.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.[34]

 
 » References Top

1.
Sanyal J, Banerjee TK, Rao VR. Dementia and cognitive impairment in patients with Parkinson's disease from India: A 7-year prospective study. Am J Alzheimers Dis Other Demen 2014;29:630-6.  Back to cited text no. 1
[PUBMED]    
2.
Marinus J, Visser M, Stiggelbout AM, Rabey JM, Martínez-Martín P, Bonuccelli U, et al. A short scale for the assessment of motor impairments and disabilities in Parkinson's disease: The SPES/SCOPA. J Neurol Neurosurg Psychiatry 2004;75:388-95.  Back to cited text no. 2
    
3.
Marinus J, Visser M, Verwey NA, Verhey FR, Middelkoop HA, Stiggelbout AM, et al. Assessment of cognition in Parkinson's disease. Neurology 2003;61:1222-8.  Back to cited text no. 3
[PUBMED]    
4.
Visser M, Verbaan D, van Rooden SM, Stiggelbout AM, Marinus J, van Hilten JJ. Assessment of psychiatric complications in Parkinson's disease: The SCOPA-PC. Mov Disord 2007;22:2221-8.  Back to cited text no. 4
    
5.
Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967;17:427-42.  Back to cited text no. 5
[PUBMED]    
6.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.  Back to cited text no. 6
[PUBMED]    
7.
Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003;2:229-37.  Back to cited text no. 7
[PUBMED]    
8.
Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005;65:1239-45.  Back to cited text no. 8
[PUBMED]    
9.
Burn DJ, Rowan EN, Minett T, Sanders J, Myint P, Richardson J, et al. Extrapyramidal features in Parkinson's disease with and without dementia and dementia with Lewy bodies: A cross-sectional comparative study. Mov Disord 2003;18:884-9.  Back to cited text no. 9
[PUBMED]    
10.
Levy G, Tang MX, Cote LJ, Louis ED, Alfaro B, Mejia H, et al. Motor impairment in PD: Relationship to incident dementia and age. Neurology 2000;55:539-44.  Back to cited text no. 10
[PUBMED]    
11.
Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D. Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 2006;21:1123-30.  Back to cited text no. 11
[PUBMED]    
12.
Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007;130(Pt 7):1787-98.  Back to cited text no. 12
    
13.
Forno LS. Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996;55:259-72.  Back to cited text no. 13
[PUBMED]    
14.
Fearnley JM, Lees AJ. Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain 1991;114(Pt 5):2283-301.  Back to cited text no. 14
[PUBMED]    
15.
Gibb WR. Idiopathic Parkinson's disease and the Lewy body disorders. Neuropathol Appl Neurobiol 1986;12:223-34.  Back to cited text no. 15
[PUBMED]    
16.
Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rüb U. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 2002;249 Suppl 3:1-5.  Back to cited text no. 16
    
17.
Jellinger KA. The pathology of Parkinson's disease. Adv Neurol 2001;86:55-72.  Back to cited text no. 17
[PUBMED]    
18.
Jellinger KA. Recent developments in the pathology of Parkinson's disease. J Neural Transm Suppl 2002;62;347-76.  Back to cited text no. 18
    
19.
Pai MC, Chan SH. Education and cognitive decline in Parkinson's disease: A study of 102 patients. Acta Neurol Scand 2001;103:243-7.  Back to cited text no. 19
[PUBMED]    
20.
Barone P, Aarsland D, Burn D, Emre M, Kulisevsky J, Weintraub D. Cognitive impairment in nondemented Parkinson's disease. Mov Disord 2011;26:2483-95.  Back to cited text no. 20
[PUBMED]    
21.
Foltynie T, Brayne CE, Robbins TW, Barker RA. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004;127(Pt 3):550-60.  Back to cited text no. 21
    
22.
Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol 1997;244:2-8.  Back to cited text no. 22
[PUBMED]    
23.
Lieberman P, Kako E, Friedman J, Tajchman G, Feldman LS, Jiminez EB. Speech production, syntax comprehension, and cognitive deficits in Parkinson's disease. Brain Lang 1992;43:169-89.  Back to cited text no. 23
[PUBMED]    
24.
Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2010;289:18-22.  Back to cited text no. 24
[PUBMED]    
25.
Goetz CG, Emre M, Dubois B. Parkinson's disease dementia: Definitions, guidelines, and research perspectives in diagnosis. Ann Neurol 2008;64 Suppl 2:S81-92.  Back to cited text no. 25
[PUBMED]    
26.
Uc EY, McDermott MP, Marder KS, Anderson SW, Litvan I, Como PG, et al. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology 2009;73:1469-77.  Back to cited text no. 26
[PUBMED]    
27.
Marder K, Tang MX, Cote L, Stern Y, Mayeux R. The frequency and associated risk factors for dementia in patients with Parkinson's disease. Arch Neurol 1995;52:695-701.  Back to cited text no. 27
[PUBMED]    
28.
Giladi N, Treves TA, Paleacu D, Shabtai H, Orlov Y, Kandinov B, et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. J Neural Transm (Vienna) 2000;107:59-71.  Back to cited text no. 28
[PUBMED]    
29.
Poewe W, Gauthier S, Aarsland D, Leverenz JB, Barone P, Weintraub D, et al. Diagnosis and management of Parkinson's disease dementia. Int J Clin Pract 2008;62:1581-7.  Back to cited text no. 29
[PUBMED]    
30.
Baldivia B, Brucki SM, Batistela S, Esper JC, Augusto CD, Rocha MS. Dementia in Parkinson's disease: A Brazilian sample. Arq Neuropsiquiatr 2011;69:733-8.  Back to cited text no. 30
[PUBMED]    
31.
Collier TJ, Kanaan NM, Kordower JH. Ageing as a primary risk factor for Parkinson's disease: Evidence from studies of non-human primates. Nat Rev Neurosci 2011;12:359-66.  Back to cited text no. 31
[PUBMED]    
32.
Adhikari S, Basu J, Das SK, Misra AK. Effects of age, stage of disease, and educational level on cognitive dysfunction in non-demented idiopathic Parkinsonism: A preliminary report. Ind Psychiatry J 2012;21:32-8.  Back to cited text no. 32
[PUBMED]  Medknow Journal  
33.
Singh S, Behari M. Verbal and visual memory in patients with early Parkinson's disease: Effect of levodopa. Neurol India 2006;54:33-7.  Back to cited text no. 33
[PUBMED]  Medknow Journal  
34.
Krishnan S, Mathuranath PS, Sarma S, Kishore A. Neuropsychological functions in progressive supranuclear palsy, multiple system atrophy and Parkinson's disease. Neurol India 2006;54:268-72.  Back to cited text no. 34
[PUBMED]  Medknow Journal  


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6]
 
 
    Tables

  [Table 1]

This article has been cited by
1 Arithmetic Errors in Financial Contexts in Parkinson’s Disease
Hannah D. Loenneker, Sara Becker, Susanne Nussbaum, Hans-Christoph Nuerk, Inga Liepelt-Scarfone
Frontiers in Psychology. 2021; 12
[Pubmed] | [DOI]
2 Domain specific cognitive impairment in Parkinson’s patients with mild cognitive impairment
Shefali Chaudhary, S Senthil Kumaran, G.S. Kaloiya, Vinay Goyal, Rajesh Sagar, M. Kalaivani, N.R. Jaganathan, Nalin Mehta, Achal Srivastava
Journal of Clinical Neuroscience. 2020; 75: 99
[Pubmed] | [DOI]
3 Non-Motor Symptoms Assessed by Non-Motor Symptoms Questionnaire and Non-Motor Symptoms Scale in Parkinsonæs Disease in Selected Asian Populations
Anna Sauerbier,Onanong Jitkritsadakul,Nataliya Titova,Lisa Klingelhoefer,Yoshio Tsuboi,Harry Carr,Hrishikesh Kumar,Rebecca Banerjee,Roberto Erro,Roongroj Bhidayasiri,Anette Schrag,Panagiotis Zis,Shen-Yang Lim,J.Y. Al-Hashel,Walaa A. Kamel,Pablo Martinez-Martin,K. Ray Chaudhuri
Neuroepidemiology. 2017; 49(1-2): 1
[Pubmed] | [DOI]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow